Serology of Paracoccidioidomycosis

Total Page:16

File Type:pdf, Size:1020Kb

Serology of Paracoccidioidomycosis View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Repositório Institucional UNIFESP Mycopathologia (2008) 165:289–302 DOI 10.1007/s11046-007-9060-5 Serology of paracoccidioidomycosis Zoilo Pires de Camargo Received: 10 July 2007 / Accepted: 30 August 2007 Ó Springer Science+Business Media B.V. 2007 Abstract This review provides the background for Keywords Antigens Á Mycosis Á understanding the role of a battery of diagnostic Paracoccidioidomycosis Á Paracoccidioides methods in paracoccidioidomycosis (PCM). This brasiliensis Á Serology systemic mycosis is a disease endemic in many regions of Latin America, with sporadic cases also occurring throughout the world (mycosis of importa- Introduction tion). Although excellent laboratory methods for diagnosis are available, there are deficiencies that The fungus Paracoccidioides brasiliensis is must be met by continued research. Understanding ensconced in the nature in Latin America, but its the uses and limitations of a battery of laboratory exact niche is not known. The expanding human and methods is essential to diagnose PCM. Clinicians and non-human populations of endemic areas provide a laboratory directors must be familiar with the uses continuing supply of individuals who are susceptible and limitations of a battery of serologic and myco- to infection with P. brasiliensis. Paracoccidioidomy- logical tests to accurately diagnose of PCM. cosis (PCM) is caused by the inhalation of conidia Antibody and antigen detections are valuable found in nature and under adverse nutritional condi- adjuncts to histopathology and culture. More tions, the fungus sporulates forming conidia which recently, the gp43 and gp70 antigen detection assay are less than 5 lm in diameter and can easily reach have improved the methodology of diagnosis of this the alveoli when inhaled, and a lung-lymph node mycosis, which improves reproducibility and facili- primary complex develops. These early lesions may tates monitoring antigen clearance during antifungal remain silent for many years and in a manner similar treatment. Furthermore, detection of antigen in cere- to tuberculosis and other systemic mycoses, they brospinal fluid and in bronchoalveolar lavage fluid may, at any time, progress in the lungs or disseminate increases the sensitivity for diagnosis of PCM in by lymphohematogenic route. central nervous system and in pulmonary infections, Serologic tests have served for several decades as respectively. aid in the diagnosis and management of paracoccid- ioidomycosis. Among the serologic tests available for Z. P. de Camargo (&) mycosis, those for paracoccidioidomycosis have been Department of Microbiology, Immunology and the most reliable and have been useful in human Parasitology, Cellular Biology Division, Federal medicine. University of Sa˜o Paulo (UNIFESP), Rua Botucatu 862/8° andar, Sao Paulo, SP 04023-062, Brazil The following serologic tests have been used for e-mail: [email protected] diagnosing PCM: tube precipitin, complement 123 290 Mycopathologia (2008) 165:289–302 fixation (CF), double immunodiffusion, counter- In 1988, we reported that a diagnostically immunoelectrophoresis (CIE), immunofluorescence, useful exocellular antigen preparation, Ag7, could radioimmunoassay, passive hemagglutination inhibi- reproducibly be produced from yeast forms of tion, immunoenzyme assays, such as ELISA, P. brasiliensis [12]. We suggested that this could be MELISA, Dot Blot, Western Blot, and more recently used as a standard method in ID tests. The method inhibition-ELISA. required, first, the determination of the number of viable cells in a 3-day old pre-inoculum, the transfer of this growth to Fernbach flask culture for 7 days, Antigen preparation the pooling of six lots consisting of three flasks each in a total of 9.9 l medium, dialysis of this filtrate, In 1916, Moses [1] was the first to use P. brasiliensis concentration by vacuum evaporation, new dialysis, antigens for serologic testing, using a saline extract and finally lyophilization. The successful use of this from the fungus, for successful testing in CF. Since this Ag7 is based on the presence of abundant amounts of study, a number of different techniques for the use and gp43, a 43,000-Da protein that is the immunodom- preparation of antigens have been described. However, inant antigen of the system and that is considered in 1955, Fava Netto [2] standardized a polysaccharide- specific for P. brasiliensis in ID tests. Since many rich P. brasiliensis antigen to use in CF tests. With this steps are necessary to obtain the final antigen test and this kind of antigen, the serology for PCM preparation, efforts were made to simplify the achieved a 90% sensitivity, thus demonstrating the methodology in order to circumvent the material usefulness of the technique not only in diagnosis but and economic difficulties found in most Latin Amer- also in monitoring the course of the disease. ican laboratories. Double immunodiffusion (ID), that involves agar Since 1993, a simplified Ag7 antigen preparation or agarose gel support, is the most used test in technique as described here has been reproduced immunodiagnosis of PCM. The preparation of culture monthly in our laboratory with very good results. The filtrate antigens and their use for immunodiagnosis of fungus was initially grown on Sabouraud medium PCM by ID were pioneered by Restrepo [3] and (SAB) slant tubes for 3 days at 35°C. At that time, Negroni [4], who observed a level of sensitivity close growth (consisting entirely of yeast cells) was to 90%. During many years their antigens were collected from at least 10 tubes, yielding an inoculum kindly supplied by them and used by almost all of approximately 2 · 106 cells. These cells were laboratories working in this area. inoculated into 500-ml Erlenmeyer flasks containing For several years, many different antigenic prep- 100 ml yeast extract-peptone-dextrose (YPD) broth arations have been used for the serodiagnosis of PCM (Difco). This culture was incubated for 3 days at by ID. These various antigens lacked a standardized 35°C on a rotatory incubator at 50 r.p.m. The growth preparation from one laboratory to another, and obtained was transferred to 1,800-ml Fernbach flasks included sonic extracts from the yeast forms, con- containing 500 ml YPD broth. The flasks were centrated filtrates, and lyophilized to cite just a few further incubated as above for 7 days. Supernatant approaches. Moreover, each antigen was prepared fluids were collected following paper filtration, from cells grown in different culture media and under concentrated under vacuum at 45°C, and dialyzed different growth conditions (such as incubation time, against distilled water. The presence of gp43 was growth temperature, size of initial inoculum, and monitored by sodium dodecyl sulfate/polyacrylamide shaken or stationary cultures). It is possible for gel electrophoresis (SDS-PAGE) followed by silver different antigenic preparations to vary considerably staining. After this step, the antigen was tested by ID. in activity and quality as a result of lack of proper lot- If positive reactions were obtained with the control to-lot production standards even within the same sera, the antigen was aliquoted and maintained at laboratory. With this variety of problems in produc- 5°C. If the reactions were negative, the antigen was ing a proper P. brasiliensis antigen, it is not concentrated again and retested. In general, concen- surprising that there is considerable disagreement tration of the filtrate 10- to 15-fold is necessary. regarding the sensitivity of the ID test for the This simplified protocol for Ag7 production has serodiagnosis of PCM [5–11]. shown a high degree of sensitivity, specificity, and 123 Mycopathologia (2008) 165:289–302 291 reproducibility in the serodiagnosis of PCM. We tissue invasion. However, these ideal situations are believe this procedure can be performed by most not always possible, and so one must often employ laboratories, even those with relatively few diagnostic approaches that are based on serologic resources. Figure 1 shows the antigenic profile of testing. In the case of PCM, serologic testing, such as Ag7. immunodiffusion, is so reliable that a positive test, even if the titer is low, is indicative of infection. The last decades show a rapidly expanding field of immunology permitting the development of several Antibody detection new techniques, which were gradually being adopted by researchers interested in the diagnosis of fungal During the process of infection, the antigens from diseases, and several methods were currently being P. brasiliensis can activate B lymphocytes which used as possible aids in diagnosing some mycotic main function is to produce immunoglobulins (Ig). infections, mainly PCM. Much of those serologic These proteins play a crucial role in defense against a assays utilize polyclonal/monoclonal antibodies or variety of infectious microorganisms; they are present antigens which can be easily quantified with high in high concentrations in body fluids and in stable sensitivity and have resulted in methods with more form. These properties led to their relative ease of sensitivity and specificity. detection and quantitation, providing major criteria The successful application of serological tests for for the presence and activity of the disease (serodi- diagnosing mycotic infections is very important agnosis), and for monitoring both evolution of the because the incidence and mortality of the mycoses, disease and response to treatment.
Recommended publications
  • The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine in This Issue
    June 2021 ISSN 1650-3414 Volume 32 Number 2 Communications and Publications Division (CPD) of the IFCC Editor-in-chief: Prof. János Kappelmayer, MD, PhD Faculty of Medicine, University of Debrecen, Hungary e-mail: [email protected] The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine In this issue Introducing the eJIFCC special issue on “POCT – making the point” Guest editor: Sergio Bernardini 116 Controlling reliability, interoperability and security of mobile health solutions Damien Gruson 118 Best laboratory practices regarding POCT in different settings (hospital and outside the hospital) Adil I. Khan 124 POCT accreditation ISO 15189 and ISO 22870: making the point Paloma Oliver, Pilar Fernandez-Calle, Antonio Buno 131 Utilizing point-of-care testing to optimize patient care James H. Nichols 140 POCT: an inherently ideal tool in pediatric laboratory medicine Siobhan Wilson, Mary Kathryn Bohn, Khosrow Adeli 145 Point of care testing of serum electrolytes and lactate in sick children Aashima Dabas, Shipra Agrawal, Vernika Tyagi, Shikha Sharma, Vandana Rastogi, Urmila Jhamb, Pradeep Kumar Dabla 158 Training and competency strategies for point-of-care testing Sedef Yenice 167 Leading POCT networks: operating POCT programs across multiple sites involving vast geographical areas and rural communities Edward W. Randell, Vinita Thakur 179 Connectivity strategies in managing a POCT service Rajiv Erasmus, Sumedha Sahni, Rania El-Sharkawy 190 POCT in developing countries Prasenjit Mitra, Praveen Sharma 195 In this issue How could POCT be a useful tool for migrant and refugee health? Sergio Bernardini, Massimo Pieri, Marco Ciotti 200 Direct to consumer laboratory testing (DTCT) – opportunities and concerns Matthias Orth 209 Clinical assessment of the DiaSorin LIAISON SARS-CoV-2 Ag chemiluminescence immunoassay Gian Luca Salvagno, Gianluca Gianfilippi, Giacomo Fiorio, Laura Pighi, Simone De Nitto, Brandon M.
    [Show full text]
  • Memoranaurns by the Participants in Signes Par Les Partici- I the Meeting
    Memoranda are state- Les Memorandums ments concerning the exposent les conclu- /e , conclusions or recom- sions et recomman- M e mmooranrantedaa mendations of certain dations de certaines / a t w / /WHO scientific meet- /reunions scientifiques ings; they are signed de /'OMS; ils sont Memoranaurns by the participants in signes par les partici- I the meeting. pants a ces reunions. Bulletin ofthe World Health Organization, 62 (2): 217-227 (1984) © World Health Organization 1984 Immunodiagnosis simplified: Memorandum from a WHO Meeting* Technologies suitable for the development ofsimplified immunodiagnostic tests were reviewed by a Working Group of the WHO Advisory Committee on Medical Research in Geneva in June 1983. They included agglutination tests and use ofartificialparticles coated with immunoglobulins, direct visual detection of antigen-antibody reactions, enzyme- immunoassays, and immunofluorescence and fluoroimmunoassays. The use of mono- clonal antibodies,in immunodiagnosis and of DNA /RNA probes to identify viruses was also discussed in detail. The needfor applicability of these tests at three levels, i.e., field conditions (or primary health care level), local laboratories, and central laboratories, was discussed and their use at thefield level was emphasized. Classical serological techniques have been used for All these tests can be carried out in laboratories that a long time for diagnostic purposes, e.g., for con- are equipped with basic instruments as well as special- firmation of clinical diagnoses, epidemiological ized apparatus (e.g., gamma counters for RIA, ultra- studies, testing of blood donors, etc. Some of these violet microscopes for IMF, etc.), which are usually techniques have been standardized to a high degree of available only in the larger, central laboratories.
    [Show full text]
  • 1995) Borrelia Burgdorferi-Specific T Lymphocytes Induce Severe Destructive Lyme Arthritis
    LTT (Lymphozyten-Proliferationstest, „Lymphozyten-Transformationstest“) Interferon Gamma Test, ELISpot (T-Cell Spot), dem Lymphozytentransformationstest bei Borreliose und bei anderen Infektionskrankheiten Im Lymphozyten-Proliferationstest, auch Lymphozyten-Transformationstest genannt (LTT), wird die Proliferationskapazität von Lymphozyten dargestellt. Der Test dient der Bewertung des Immunstatus oder der Diagnose einer speziellen Sensibilisierung. In the Lymphocyte proliferation assay, also known as lymphocyte transformation test (LTT), the proliferation capacity of lymphocytes is shown. The test is used to evaluate the immune status or the diagnosis of specific sensitization of an object. Im Interferon Gamma Test, dem ELISPOT (Enzyme-Linked ImmunoSpot), auch T- Cellspot genannt, wird durch die Bestimmung der Zytokin – Produktion die Quantität und die Qualität einer T – Zell - Immunantwort zeitnah dokumentiert. In the Interferone Gamma Test, ELISPOT (Enzyme-Linked ImmunoSpot), also called T-Cell spot, represented by the determination of cytokine – Production, the quantity and quality of T - cell - immune response in a timely manner is documented. Lim LC, England DM, DuChateau BK, Glowacki NJ, Schell RF (1995) Borrelia burgdorferi-specific T lymphocytes induce severe destructive Lyme arthritis. Infect. Immun. 63, 1400-1408. Dwyer JM et al. (1979) Behavior of human immunoregulatory cells in culture. L Variables requiring consideration for clinical studies. Clin Exp Immunol 38, 499-513 Johnson C, Dwyer JM (1981) Quantitation of spontaneous suppressor cell activity in human cord blood lymphocytes and their behavior in culture (abstract). Fed Proc 40, 1075 Czerkinsky C, Nilsson L, Nygren H, Ouchterlony O, Tarkowski A (1983) A solid-phase enzyme- linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.J Immunol Methods 65 (1–2), 109–121.
    [Show full text]
  • Ampath Medical Surveillance Guidelines Metal Chemicals
    AMPATH MEDICAL SURVEILLANCE GUIDELINES METAL CHEMICALS TABLE OF CONTENTS Introduction 3 Definitions 4 Biological monitoring 7 Biological effect monitoring 15 Health program 15 Food handler’s health program 16 Driver’s health program 16 Substance abuse in the workplace 17 Alcohol in the workplace 17 Target organs for alcohol abuse 21 Drugs in the workplace 22 Ampath drugs of abuse screening and confirmatory tests on urine 23 Conditions under which a pathologist will testify in court 23 Chain of custody 24 Hazardous chemical regulations 25 Designing and implementing a program of medical surveillance 25 Assessment of potential exposure 25 Table 3 substances 26 Available tests 27 Test interpretation 31 Ampath Quality Assurance 33 Designing exposure profiles 34 Work related hazardous chemical exposure 36 Chemical exposure: DNA adducts 37 Target organs for chemical exposure 39 Chemical exposure profiles 40 Aniline 40 Acetone 41 Benzene 42 Carbon disulphide 43 Carbon monoxide 44 Cyanide 45 Ethyl benzene 46 NN-dimethylformamide 47 Furfural 48 N-hexane 49 © Ampath Medical Surveillance Guideline 1 Isocyanate 50 Methanol 51 Methyl chloroform 52 Methyl ethyl ketone 53 Methyl isobutyl ketone 54 Nitrobenzene 55 Organophosphorous cholinesterase inhibitors 56 Paraquat 57 Parathion 58 Pentachlorophenol 59 Perchloroethylene 60 Phenol 61 Polycyclic aromatic hydrocarbon(PAH) 62 Styrene 64 Toluene 65 Trichloroethylene 67 Xylene 68 Metals 69 Diagnosis and investigation of occupational exposure to metals; a general review 69 Target organs for metal exposure
    [Show full text]
  • Ampath Desk Reference: Guide to Laboratory Tests
    Ampath Guide to Lab Tests front cover final repro outlines 15 March 2016.
    [Show full text]
  • Abstracts of Poster Presentations
    Abstracts of Poster Presentations To view the full program, please visit the Congress website www.kenes.com/aps Downloaded from lup.sagepub.com at University Library Utrecht on March 17, 2015 loth ktertSic (Qn nsanAtiopuipdAMibocEes PFates 584 ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH DEVELOPMENT OF ANTIPHOSDPHOLIPID-ANTIBODIES AND INTOLERANCE TO METALS IN THE ORAL CAVITY FACrOR V-INHIBITOR AFTER CIPROFLOXACIN IN TWO CASES H. Kucerova', J. Prochazkovat, I. Janatkova2, J. Bartova', T. Fucikova2 W.Miesbachl, J. Vogte, D. Peez3, B. Buehler', G. Asmelashl', 'Institute ofDental Research, 1st Medical Faculty, 2Institute ofClinical 1. Scharrerl Imnmunology andAllergology, General Faculty Hospital, Prague, 'J W.Goethe-University, Frankfurt, 25t. Vincenz Hospital, Mainz, Czech Republic 3Justus Liebig University, Frankfurt, Germany Dental alloys are not a physiological part of the organism. Metals can cause The development of factor V-inhibitor is very rare, especially in the production of autoantibodies in sensitive individuals as well as other combination with the antiphospholipid (aPL)-antibodies. The present paper undesired side effects. The aim of this presentation is to evaluate the describes two patients with factor V-inhibitor and aPL-antibodies after presence of antiphospholipid antibodies in sera of patients with oral trcatment with ciprofloxacin. Lupus anticoagulants (LA) were assayed discomfort and the occurrence of pathological galvanic currents in the oral according to the criteria of SSC of the ISTH, ACL by an ELISA, factor V- cavity. The patients were diagnosed by measurement of galvanic features inhibitor by the Bethesda method. with the device Odontologic accompanied by the modified method ofblastic Q.Oe.atirti 74 years old was treated with ciprofloxacin for a postoperative transfonnation for metals (Melisa) and by the anamnestic data.
    [Show full text]
  • Radioimmunoassay in Developing Countries: General Principles
    XA9847613 Chapter 16 RADIOIMMUNOASSAY IN DEVELOPING COUNTRIES (General principles) R.D. Piyasena Radioimmunoassay (RIA) is probably the most commonly performed nuclear medicine technique. It is an in vitro procedure, where no radioactivity is administered to the patient. But this alone is not the reason for its widespread use. It provides the basis for extremely sensitive and specific diagnostic tests, and its use in present day medicine has brought a virtual information explosion in terms of understanding the pathophysiology of many diseases. The fact that the technology involved is within the technical and economic capabilities of the developing world is evident from the increasing demand for its introduction or expansion of existing services. RIA facilities need not be restricted to urban hospitals, as in the case of in vivo nuclear medicine techniques, but may be extended to smaller district hospitals and other laboratories in peripheral areas. It is also possible to send blood samples to a central laboratory so that a single centre can serve a wide geographical area. There are many laboratories in the industrialized world that receive a major proportion of samples for assay by mail. In recent years, substantial RIA services have been established in many of the developing countries in Asia and Latin America. The International Atomic Energy Agency (IAEA) and World Health Organisations (WHO) have made vital contributions to these activities and have played a catalytic role in assisting member states to achieve realistic goals. In the past five years, more than 250 individual RIA laboratories in developing member states have been beneficiaries of IAEA projects.
    [Show full text]
  • XXI Fungal Genetics Conference Abstracts
    Fungal Genetics Reports Volume 48 Article 17 XXI Fungal Genetics Conference Abstracts Fungal Genetics Conference Follow this and additional works at: https://newprairiepress.org/fgr This work is licensed under a Creative Commons Attribution-Share Alike 4.0 License. Recommended Citation Fungal Genetics Conference. (2001) "XXI Fungal Genetics Conference Abstracts," Fungal Genetics Reports: Vol. 48, Article 17. https://doi.org/10.4148/1941-4765.1182 This Supplementary Material is brought to you for free and open access by New Prairie Press. It has been accepted for inclusion in Fungal Genetics Reports by an authorized administrator of New Prairie Press. For more information, please contact [email protected]. XXI Fungal Genetics Conference Abstracts Abstract XXI Fungal Genetics Conference Abstracts This supplementary material is available in Fungal Genetics Reports: https://newprairiepress.org/fgr/vol48/iss1/17 : XXI Fungal Genetics Conference Abstracts XXI Fungal Genetics Conference Abstracts Plenary sessions Cell Biology (1-87) Population and Evolutionary Biology (88-124) Genomics and Proteomics (125-179) Industrial Biology and Biotechnology (180-214) Host-Parasite Interactions (215-295) Gene Regulation (296-385) Developmental Biology (386-457) Biochemistry and Secondary Metabolism(458-492) Unclassified(493-502) Index to Abstracts Abstracts may be cited as "Fungal Genetics Newsletter 48S:abstract number" Plenary Abstracts COMPARATIVE AND FUNCTIONAL GENOMICS FUNGAL-HOST INTERACTIONS CELL BIOLOGY GENOME STRUCTURE AND MAINTENANCE COMPARATIVE AND FUNCTIONAL GENOMICS Genome reconstruction and gene expression for the rice blast fungus, Magnaporthe grisea. Ralph A. Dean. Fungal Genomics Laboratory, NC State University, Raleigh NC 27695 Rice blast disease, caused by Magnaporthe grisea, is one of the most devastating threats to food security worldwide.
    [Show full text]
  • MSACL 2014 EU September 1 Austria 2-5, 2014 Salzburg, Con Dence in Results MSACL 2014 EU
    The Association for MS Mass Spectrometry: ACL Applications to the Clinical Lab MSACL 2014 EU September 2-5, 2014 Salzburg, Austria 1 2014 EU September MSACL Condence in Results MSACL 2014 EU ™ high-performance medical devices for in vitro diagnostic use ™ Prelude MD ™ ™ Endura MD ™ mass spectrometer, and Thermo Salzburg, Austria ™ ClinQuan MD ™ LC-MS for in vitro diagnostic use September 2-5 The 1st Annual European Congress Visit us in booth #12 • st Annual European Congress Program Congress Annual European e licensed for limited use only to Thermo r d parties including Shutterstock, and a r by thi Supported in part by generous contributions from: For in vitro diagnostic use. Not available in all countries. San Jose, CA USA i s Endura MD Mass ISO 13485 Prelude MD HPLC Spectrometer ClinQuan MD Software AD64157-EN 0614S-Rev.B MSACLMASS SPECTROMETRY SOLUTIONS FOR IN2014 VITRO DIAGNOSTICS EU The variety of your clinical research Salzburg, Austria demands a variety of technologies September 2-5 The 1st Annual European Congress You’re not the only one who needs to trust the test results ACCURACY THE FIRST TIME No one analytical technology can adequately reveal everything you need ! GC-Triple Quadrupole to know about your sample. Bruker offers the broadest range of high ! LC-Triple Quadrupole Clinicians and patients count on the most reliable diagnostic answers. We want you to be confident that results are as timely performance, easy-to-use, and expertly supported analytical systems ! LC-QqTOF and accurate as possible. SCIEX Diagnostics offers an in vitro diagnostics solution with exceptional assay performance that helps to overcome any clinical research challenge.
    [Show full text]
  • August 2021 Vectorborne Infectious Diseases
    1913.),Culebra Jonas( OilLie Cut, on(1880−1940) canvas, Panama 60 Canal in The x 50 Conquerors in/ 152.4 cm x 127 cm. InfectiousDiseases Vectorborne Image copyright © The Metropolitan Museum of Art, New York, NY, United States. Image source: Art Resource, New York, NY, United States. August 2021 ® Peer-Reviewed Journal Tracking and Analyzing Disease Trends Pages 2008–2250 ® EDITOR-IN-CHIEF D. Peter Drotman ASSOCIATE EDITORS EDITORIAL BOARD Charles Ben Beard, Fort Collins, Colorado, USA Barry J. Beaty, Fort Collins, Colorado, USA Ermias Belay, Atlanta, Georgia, USA Martin J. Blaser, New York, New York, USA David M. Bell, Atlanta, Georgia, USA Andrea Boggild, Toronto, Ontario, Canada Sharon Bloom, Atlanta, Georgia, USA Christopher Braden, Atlanta, Georgia, USA Richard Bradbury, Melbourne, Australia Arturo Casadevall, New York, New York, USA Corrie Brown, Athens, Georgia, USA Benjamin J. Cowling, Hong Kong, China Kenneth G. Castro, Atlanta, Georgia, USA Michel Drancourt, Marseille, France Christian Drosten, Charité Berlin, Germany Paul V. Effler, Perth, Australia Isaac Chun-Hai Fung, Statesboro, Georgia, USA Anthony Fiore, Atlanta, Georgia, USA Kathleen Gensheimer, College Park, Maryland, USA David O. Freedman, Birmingham, Alabama, USA Rachel Gorwitz, Atlanta, Georgia, USA Peter Gerner-Smidt, Atlanta, Georgia, USA Duane J. Gubler, Singapore Stephen Hadler, Atlanta, Georgia, USA Scott Halstead, Arlington, Virginia, USA Matthew J. Kuehnert, Edison, New Jersey, USA Nina Marano, Atlanta, Georgia, USA David L. Heymann, London, UK Martin I. Meltzer, Atlanta, Georgia, USA Keith Klugman, Seattle, Washington, USA David Morens, Bethesda, Maryland, USA S.K. Lam, Kuala Lumpur, Malaysia J. Glenn Morris, Jr., Gainesville, Florida, USA Shawn Lockhart, Atlanta, Georgia, USA Patrice Nordmann, Fribourg, Switzerland John S.
    [Show full text]
  • Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral
    ORIGINAL RESEARCH published: 07 May 2021 doi: 10.3389/fimmu.2021.643298 Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral Cancer Is Associated With CCR8 Expression and Rapid Membrane Edited by: Vitamin D Signaling Pathway Lewis Z. Shi, University of Alabama at Birmingham, 1 ´ 2 3,4,5 1 United States Marco Fraga , Milly Yañez , Macarena Sherman , Faryd Llerena , Mauricio Hernandez 6, Guillermo Nourdin 6, Francisco A´ lvarez 6, Joaqu´ın Urrizola 7, Reviewed by: Ce´ sar Rivera 8, Liliana Lamperti 1,9, Lorena Nova 10, Silvia Castro 1, Omar Zambrano 11, Hongru Zhang, 11 ´ 12 12 12 12 University of Pennsylvania, Alejandro Cifuentes , Leon Campos , Sergio Moya , Juan Pastor , Marcelo Nuñez , 12 12 ´ 1 ´ 13 14 United States Jorge Gatica , Jorge Figueroa , Felipe Zuñiga , Carlos Salomon , Gustavo Cerda , 5 1 15 16 Greg M. Delgoffe, Ricardo Puentes , Gonzalo Labarca , Mabel Vidal , Reuben McGregor 1 University of Pittsburgh, and Estefania Nova-Lamperti * United States 1 Molecular and Translational Immunology Laboratory, Clinical Biochemistry and Immunology Department, Pharmacy Faculty, *Correspondence: Universidad de Concepcio´ n, Concepcio´ n, Chile, 2 Anatomy Pathology Unit and Dental Service, Oral Pathology Department, Estefania Nova-Lamperti Hospital Las Higueras, Talcahuano, Chile, 3 Anatomy Pathology Unit, Hospital Guillermo Grant Benavente and Universidad [email protected]; de Concepcio´ n, Concepcio´ n, Chile, 4 Head and Neck Service, Hospital Guillermo Grant Benavente, Concepcio´ n, Chile, [email protected] 5 Dental
    [Show full text]
  • Frequently Asked Questions
    Frequently Asked Questions 03-DFAQ-02a version 1 Contents 1. COMMERCIAL INFORMATION .................................................................................................... 4 1.1. How can I place an order? ...........................................................................................................4 1.2. How can I obtain a price? ............................................................................................................4 1.3. Does DIAsource provide the kit components separately? ...........................................................4 1.4. How can I address a complaint? ..................................................................................................4 2. REGULATORY INFORMATION ..................................................................................................... 4 2.1. Do the DIAsource kits contain dangerous substances? ...............................................................4 2.2. Are the DIAsource assays CE mark and/or FDA approved? .........................................................4 2.3. May the DIAsource assays be sold in Canada? ............................................................................5 3. TECHNICAL INFORMATION ......................................................................................................... 5 3.1. How can I receive a technical information? ................................................................................5 3.2. What is the principle of an immunoassay (ELISA – RIA – IRMA)? ................................................5
    [Show full text]